<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00423761</url>
  </required_header>
  <id_info>
    <org_study_id>CRH103152</org_study_id>
    <nct_id>NCT00423761</nct_id>
  </id_info>
  <brief_title>An Investigation To Determine The Potential Interaction Effect Between GW876008 And Midazolam.</brief_title>
  <official_title>An Open-Label, Single-Sequence Study to Evaluate the Potential CYP 3A4 Pharmacokinetic Interaction of GW876008 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This study will evaluate any effect of single and repeated administration of GW876008 on the
      metabolism of midazolam in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood levels of GW876008 and midazolam collected on Day 1 of Session 1 and on Days 1 and 14 of Session 2.</measure>
    <time_frame>on Day 1 of Session 1 and on Days 1 and 14 of Session 2.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>12-lead ECG, Continuous Lead II Telemetry &amp; adverse events: day 1 session 1; days 1 &amp; 14 session 2</measure>
    <time_frame>day 1 session 1; days 1 &amp; 14 session 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vital signs &amp; clinical laboratory data: day 1 session 1; days 1, 7 &amp; 14 session 2</measure>
    <time_frame>day 1 session 1; days 1, 7 &amp; 14 session 2</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy Subjects</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW876008</intervention_name>
    <other_name>midazolam</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males or females.

          -  Normal ECG.

          -  Agree to remain in the clinic for the time defined in the protocol.

          -  Subjects must agree to abstain from alcohol for 24 hours prior to the start of dosing
             until collection of the final pharmacokinetic sample.

        Exclusion Criteria:

          -  Any serious medical disorder or condition.

          -  Any history of an endocrine disorder.

          -  Any clinically significant laboratory abnormality.

          -  History of psychiatric illness.

          -  Any history of suicidal attempts or behavior.

          -  Active peptic ulcer disease.

          -  Positive faecal occult blood.

          -  The subject smokes or has smoked or has used any nicotine-containing products in the
             last six months.

          -  Women having a positive serum HCG pregnancy test at screening, a positive urine
             pregnancy test before admission to the Unit during the in-house periods, who are not
             willing to use acceptable methods of contraception or who are lactating or planning to
             become pregnant within the three months following the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MBChB, MFPM</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2007</study_first_submitted>
  <study_first_submitted_qc>January 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2007</study_first_posted>
  <last_update_submitted>May 15, 2009</last_update_submitted>
  <last_update_submitted_qc>May 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>GSK</organization>
  </responsible_party>
  <keyword>Pharmacokinetics,</keyword>
  <keyword>tolerability,</keyword>
  <keyword>healthy,</keyword>
  <keyword>subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

